Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Identification of a tumor-specific allo-HLA-restricted γδTCR.

Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, Falkenburg JH, Bongiovanni L, de Bruin A, Vargas-Diaz D, Altelaar M, Heck AJR, Shultz LD, Ishikawa F, Nishimura MI, Sebestyén Z, Kuball J.

Blood Adv. 2019 Oct 8;3(19):2870-2882. doi: 10.1182/bloodadvances.2019032409.

2.

Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells.

Johanna I, Straetemans T, Heijhuurs S, Aarts-Riemens T, Norell H, Bongiovanni L, de Bruin A, Sebestyen Z, Kuball J.

J Immunother Cancer. 2019 Mar 12;7(1):69. doi: 10.1186/s40425-019-0558-4.

3.

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T.

Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5. No abstract available.

4.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T.

Clin Cancer Res. 2013 Oct 15;19(20):5591-601. doi: 10.1158/1078-0432.CCR-12-3676. Epub 2013 Sep 4.

5.

Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen.

Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T, Bloem AC, Storm G, Martens AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2010 Nov 15;16(22):5481-8. doi: 10.1158/1078-0432.CCR-10-1340. Epub 2010 Nov 9.

6.

Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.

Aarts-Riemens T, Emmelot ME, Verdonck LF, Mutis T.

Eur J Immunol. 2008 May;38(5):1381-90. doi: 10.1002/eji.200737590.

7.

Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.

Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB.

Clin Cancer Res. 2006 Sep 15;12(18):5520-5.

8.

Supplemental Content

Loading ...
Support Center